Merck and ENGC are in line for exits after Electrocore, the developer of a nerve stimulation treatment for headaches, filed to raise up to $74.8m.
US-based bioelectronic medicine developer Electrocore filed for a $74.8m initial public offering on Monday that will allow pharmaceutical firm Merck & Co and medical device maker ENGC to exit.
Electrocore has developed a nerve-stimulation device, GammaCore, that has received regulatory approval as a treatment for pain caused by migraines and episodic cluster headaches.
The IPO proceeds will go to recruitment, as Electrocore looks to hire business managers and expand marketing for GammaCore in the US, as well as on research and…
